Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction
暂无分享,去创建一个
J G Turner | H Ikram | C. Frampton | A. Richards | E. Espiner | M. Nicholls | H. Ikram | I. Crozier | T. Yandle | J. Lainchbury | A M Richards | M G Nicholls | T G Yandle | E A Espiner | R C Buttimore | J G Lainchbury | J M Elliott | C Frampton | I G Crozier | D W Smyth | J. Elliott | J. Turner | R. C. Buttimore | D. Smyth
[1] A. Struthers,et al. Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction , 1993, The Lancet.
[2] J. Cohn,et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.
[3] C W Parker,et al. Radioimmunoassay for cyclic nucleotides. I. Preparation of antibodies and iodinated cyclic nucleotides. , 1972, The Journal of biological chemistry.
[4] A. Richards,et al. Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. , 1993, The Journal of clinical endocrinology and metabolism.
[5] H. Fillit,et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.
[6] K. Bailey,et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. , 1996, Hypertension.
[7] M. Yacoub,et al. Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy , 1996, The Lancet.
[8] S. Yusuf,et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.
[9] R. Bonow,et al. New insights into the cardiac natriuretic peptides. , 1996, Circulation.
[10] A. Steiner. Radioimmunoassay for the cyclic nucleotides. , 1973, Pharmacological reviews.
[11] S. Anker,et al. Metabolic, functional, and haemodynamic staging for CHF? , 1996, The Lancet.
[12] N. Kennedy,et al. Comparison of atrial natriuretic peptide B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. , 1996, The American journal of cardiology.
[13] C. Lang,et al. Diagnostic value of B-type natriuretic peptide concentrations in patients with acute myocardial infarction. , 1996, The American journal of cardiology.
[14] R. T. Lie,et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. , 1996, Circulation.
[15] R. T. Lie,et al. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. , 1994, Circulation.
[16] H. Teufelsbauer,et al. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension. , 1993, The American journal of cardiology.
[17] E. Espiner,et al. Radioimmunoassay and characterization of atrial natriuretic peptide in human plasma. , 1986, The Journal of clinical endocrinology and metabolism.
[18] J. Hanley,et al. The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.
[19] G. Lamas,et al. N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. , 1994, Circulation.
[20] T. Pindborg,et al. Plasma concentration of atrial natriuretic peptide at admission and risk of cardiac death in patients with acute myocardial infarction , 1992, British heart journal.
[21] K. Minaker,et al. Atrial natriuretic peptide levels in the prediction of congestive heart failure risk in frail elderly. , 1992, JAMA.
[22] J. Izzo,et al. Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in man. , 1981, Life sciences.
[23] E. Braunwald,et al. Prognostic value of N-terminal proatrial natriuretic factor plasma levels measured within the first 12 hours after myocardial infarction. Thrombolysis in Myocardial Infarction (TIMI) II Investigators. , 1995, Journal of the American College of Cardiology.
[24] N. Arakawa,et al. Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction. , 1996, Journal of the American College of Cardiology.
[25] C R Benedict,et al. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. , 1996, Circulation.
[26] K. Bailey,et al. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction , 1993, The Lancet.
[27] G. Maurer,et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. , 1996, Journal of the American College of Cardiology.
[28] K. Dickstein,et al. Plasma proatrial natriuretic factor is predictive of clinical status in patients with congestive heart failure. , 1995, The American journal of cardiology.
[29] S. Anker,et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. , 1997, Circulation.
[30] R. T. Lie,et al. Prognostic value of plasma atrial natriuretic factor, norepinephrine and epinephrine in acute myocardial infarction. , 1993, The American journal of cardiology.